Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype

The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele. However, there is a group of patients, in addition to those with rare mutations, in which despite the presence of a F508del in one allele, it was not possible to identify any mutation in the other allele. To date, these patients are excluded from treatment with Trikafta in Italy, where the CF patients carrying F508del/unknown represent about 1.3% (71 patients) of the overall Italian CF patients. In this paper we show that the Trikafta treatment of nasal epithelial cells, derived from F508del/Unknown patients, results in a significant rescue of CFTR activity. Based on our findings, we think that the F508del/Unknown patients considered in this study could obtain clinical benefits from Trikafta treatment, and we strongly suggest their eligibility for this type of treatment. This study, adding further evidence in the literature, once again confirms the validity of functional studies on nasal cells in the cystic fibrosis theratyping and personalized medicine.

[1]  J. Brewington,et al.  Nasal Epithelial Cell-Based Models for Individualized Study in Cystic Fibrosis , 2021, International journal of molecular sciences.

[2]  G. Castaldo,et al.  Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype , 2021, Molecular genetics & genomic medicine.

[3]  D. Taruscio,et al.  [Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018]. , 2021, Epidemiologia & Prevenzione.

[4]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[5]  D. Taruscio,et al.  [Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016]. , 2019, Epidemiologia e prevenzione.

[6]  C. Braggion,et al.  Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): Experience in Tuscany, Italy. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  G. Castaldo,et al.  Two CFTR mutations within codon 970 differently impact on the chloride channel functionality , 2019, Human mutation.

[8]  C. Goss,et al.  The future of cystic fibrosis care: a global perspective. , 2020, The Lancet. Respiratory medicine.

[9]  E. Caci,et al.  In vitro Methods for the Development and Analysis of Human Primary Airway Epithelia , 2018, Front. Pharmacol..

[10]  M. Guill,et al.  Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis , 2018, Annals of the American Thoracic Society.

[11]  V. Raia,et al.  S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy , 2018, Italian Journal of Pediatrics.

[12]  R. Ravazzolo,et al.  High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel , 2017, The Journal of Biological Chemistry.

[13]  J. Jais,et al.  Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators , 2017, Scientific Reports.

[14]  V. Raia,et al.  An "ex vivo model" contributing to the diagnosis and evaluation of new drugs in cystic fibrosis , 2017, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[15]  E. Ingenito,et al.  Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.

[16]  V. Raia,et al.  Genotype–phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles , 2016, Journal of Medical Genetics.

[17]  W. T. Harris,et al.  Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. , 2016, The Lancet. Respiratory medicine.

[18]  Garry R. Cutting,et al.  From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations , 2016, Molecular biology of the cell.

[19]  Salvador Martínez-Bartolomé,et al.  ΔF508 CFTR interactome remodeling promotes rescue of Cystic Fibrosis , 2015, Nature.

[20]  J. Mainz,et al.  Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. , 2013, American journal of respiratory and critical care medicine.

[21]  M. Monti,et al.  Molecular and functional analysis of the large 5' promoter region of CFTR gene revealed pathogenic mutations in CF and CFTR-related disorders. , 2013, The Journal of molecular diagnostics : JMD.

[22]  G. Castaldo,et al.  Gene Mutation in MicroRNA Target Sites of CFTR Gene: A Novel Pathogenetic Mechanism in Cystic Fibrosis? , 2013, PloS one.

[23]  B. Kerem,et al.  Consensus on the Use and Interpretation of Cystic Fibrosis Mutation Analysis in Clinical Practice , 2022 .